93 results
S-3ASR
DAWN
Day One Biopharmaceuticals, Inc.
28 Aug 24
Automatic shelf registration
4:07pm
opportunities, nonclinical and clinical development activities, efficacy and safety profile of our product candidates, potential therapeutic benefits … and economic value of our product candidates, use of net proceeds from our public offerings, our ability to maintain and recognize the benefits
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
-grade glioma (pLGG) or related indications, the potential therapeutic benefits and economic value of our products and product candidates, potential
8-K
EX-99.3
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
7:35am
indications, the potential therapeutic benefits and economic value of our products and product candidates, potential growth opportunities, competitive position
8-K
EX-10.1
i3p1rk6bemkmxohegqo
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-10.2
k7ojxr
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
8-K
EX-99.2
s6wd6
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
8-K
EX-99.1
4wyayih0
12 Jun 24
Regulation FD Disclosure
8:07am
8-K
EX-99.2
01j 2je1a
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
8-K
EX-99.2
ux0m1h7
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
75bulhpcfp18dyf9ud
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
gcs8j uv5uj4e
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
kwyjf
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
gioqd iuuu
8 Jan 24
Regulation FD Disclosure
8:30am
S-8
EX-99.2
1bkmbgkvz0s
4 Jan 24
Registration of securities for employees
4:06pm